These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33255642)

  • 1.
    Kukhar Y; Smagulova A; Daniyarova A; Baiduissenova A; Kiyan V
    J Fungi (Basel); 2020 Nov; 6(4):. PubMed ID: 33255642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different toenail onychomycosis due to
    Ge G; Li D; Mei H; Lu G; Zheng H; Liu W; Shi D
    Med Mycol Case Rep; 2019 Jun; 24():69-71. PubMed ID: 31080710
    [No Abstract]   [Full Text] [Related]  

  • 3. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
    Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
    Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis.
    Miranda-Cadena K; Marcos-Arias C; Mateo E; Aguirre JM; Quindós G; Eraso E
    Arch Oral Biol; 2018 Nov; 95():100-107. PubMed ID: 30096698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.
    Pfaller MA; Messer SA; Bolmström A; Odds FC; Rex JH
    J Clin Microbiol; 1996 Jul; 34(7):1691-3. PubMed ID: 8784571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of
    Kukhar E; Smagulova A; Kiyan V
    Med Mycol Case Rep; 2020 Mar; 27():55-58. PubMed ID: 31993320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of Candida species to antifungal agents used in the treatment of onychomycosis: a review of current problems.
    Evans EG
    Br J Dermatol; 1999 Nov; 141 Suppl 56():33-5. PubMed ID: 10730912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection.
    Sav H; Baris A; Turan D; Altinbas R; Sen S
    Microb Pathog; 2018 Mar; 116():257-262. PubMed ID: 29378232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onychomycosis in Tehran, Iran: prevailing fungi and treatment with itraconazole.
    Khosravi AR; Mansouri P
    Mycopathologia; 2001; 150(1):9-13. PubMed ID: 11392568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification and antifungal susceptibility profiles of Candida parapsilosis complex species isolated from culture collection of clinical samples.
    Ataides FS; Costa CR; Souza LK; Fernandes Od; Jesuino RS; Silva Mdo R
    Rev Soc Bras Med Trop; 2015; 48(4):454-9. PubMed ID: 26312937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal agent susceptibilities and interpretation of Malassezia pachydermatis and Candida parapsilosis isolated from dogs with and without seborrheic dermatitis skin.
    Yurayart C; Nuchnoul N; Moolkum P; Jirasuksiri S; Niyomtham W; Chindamporn A; Kajiwara S; Prapasarakul N
    Med Mycol; 2013 Oct; 51(7):721-30. PubMed ID: 23547880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
    Martín E; Parras P; Lozano MC
    Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report and review. Onychomycosis due to Candida parapsilosis.
    Gautret P; Rodier MH; Kauffmann-Lacroix C; Jacquemin JL
    Mycoses; 2000; 43(11-12):433-5. PubMed ID: 11204360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of Candida parapsilosis in onychomycosis. An epidemiological survey in Israel.
    Segal R; Kimchi A; Kritzman A; Inbar R; Segal Z
    Mycoses; 2000 Oct; 43(9-10):349-53. PubMed ID: 11105538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virulence properties and sensitivity profile of Candida parapsilosis complex species and Kodamaea ohmeri isolates from onychomycosis of HIV/AIDS patients.
    Ferreira EO; Mendes INVF; Monteiro SG; Crosara KTB; Siqueira WL; de Maria Pedroso Silva de Azevedo C; Moffa EB; de Andrade Monteiro C
    Microb Pathog; 2019 Jul; 132():282-292. PubMed ID: 31082527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole, itraconazole and ketoconazole in vitro activity against Candida spp.
    Arévalo MP; Arias A; Andreu A; Rodríguez C; Sierra A
    J Chemother; 1994 Aug; 6(4):226-9. PubMed ID: 7830098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal Susceptibility Analysis of Clinical Isolates of Candida parapsilosis in Iran.
    Lotfali E; Kordbacheh P; Mirhendi H; Zaini F; Ghajari A; Mohammadi R; Noorbakhsh F; Moazeni M; Fallahi A; Rezaie S
    Iran J Public Health; 2016 Mar; 45(3):322-8. PubMed ID: 27141494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species distribution and antifungal susceptibility patterns of Candida species: Is low susceptibility to itraconazole a trend in Malaysia?
    Santhanam J; Nazmiah N; Aziz MN
    Med J Malaysia; 2013 Aug; 68(4):343-7. PubMed ID: 24145264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.